482 related articles for article (PubMed ID: 26108356)
1. Novel drugs in clinical development for hepatocellular carcinoma.
Waidmann O; Trojan J
Expert Opin Investig Drugs; 2015; 24(8):1075-82. PubMed ID: 26108356
[TBL] [Abstract][Full Text] [Related]
2. Tivantinib: critical review with a focus on hepatocellular carcinoma.
Rota Caremoli E; Labianca R
Expert Opin Investig Drugs; 2014 Nov; 23(11):1563-74. PubMed ID: 25307444
[TBL] [Abstract][Full Text] [Related]
3. New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?
Woo HY; Yoo SY; Heo J
Expert Opin Pharmacother; 2017 Jan; 18(1):35-44. PubMed ID: 27849399
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?
Brizzi MP; Pignataro D; Tampellini M; Scagliotti GV; Di Maio M
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1053-62. PubMed ID: 27548441
[TBL] [Abstract][Full Text] [Related]
5. [New Systemic Therapies for Advanced Hepatocellular Carcinoma].
Kim DY
Korean J Gastroenterol; 2019 Jan; 73(1):10-15. PubMed ID: 30690953
[TBL] [Abstract][Full Text] [Related]
6. Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.
Hollebecque A; Malka D; Ferté C; Ducreux M; Boige V
Eur J Cancer; 2015 Feb; 51(3):327-39. PubMed ID: 25559615
[TBL] [Abstract][Full Text] [Related]
7. Oral chemotherapy for the treatment of hepatocellular carcinoma.
Yamamoto S; Kondo S
Expert Opin Pharmacother; 2018 Jun; 19(9):993-1001. PubMed ID: 29913090
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?
Oikonomopoulos G; Aravind P; Sarker D
Future Oncol; 2016 Feb; 12(4):465-76. PubMed ID: 26785762
[TBL] [Abstract][Full Text] [Related]
9. Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma.
Trojan J; Waidmann O
J Hepatocell Carcinoma; 2016; 3():31-36. PubMed ID: 27703962
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
[TBL] [Abstract][Full Text] [Related]
11. Treating advanced hepatocellular carcinoma: How to get out of first gear.
Harding JJ; Abou-Alfa GK
Cancer; 2014 Oct; 120(20):3122-30. PubMed ID: 24898783
[TBL] [Abstract][Full Text] [Related]
12. Regorafenib for the treatment of unresectable hepatocellular carcinoma.
Rimassa L; Pressiani T; Personeni N; Santoro A
Expert Rev Anticancer Ther; 2017 Jul; 17(7):567-576. PubMed ID: 28580808
[TBL] [Abstract][Full Text] [Related]
13. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
Scartozzi M; Faloppi L; Svegliati Baroni G; Loretelli C; Piscaglia F; Iavarone M; Toniutto P; Fava G; De Minicis S; Mandolesi A; Bianconi M; Giampieri R; Granito A; Facchetti F; Bitetto D; Marinelli S; Venerandi L; Vavassori S; Gemini S; D'Errico A; Colombo M; Bolondi L; Bearzi I; Benedetti A; Cascinu S
Int J Cancer; 2014 Sep; 135(5):1247-56. PubMed ID: 24510746
[TBL] [Abstract][Full Text] [Related]
14. Systemic therapy of hepatocellular carcinoma: current and promising.
Kalyan A; Nimeiri H; Kulik L
Clin Liver Dis; 2015 May; 19(2):421-32. PubMed ID: 25921671
[TBL] [Abstract][Full Text] [Related]
15. The evolving landscape of therapeutic drug development for hepatocellular carcinoma.
Chong DQ; Tan IB; Choo SP; Toh HC
Contemp Clin Trials; 2013 Nov; 36(2):605-15. PubMed ID: 23591326
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
17. MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.
Facciorusso A; Licinio R; Carr BI; Di Leo A; Barone M
Expert Rev Gastroenterol Hepatol; 2015 Jul; 9(7):993-1003. PubMed ID: 25915713
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
[TBL] [Abstract][Full Text] [Related]
19. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
Ikeda M; Kobayashi M; Tahara M; Kaneko S
Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists.
Lee SJ; Lim HY
Expert Opin Emerg Drugs; 2017 Jun; 22(2):191-200. PubMed ID: 28506080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
